Tesamorelin (10mg)

Quickstart Highlights

Tesamorelin (a GHRH analog) is administered as a once-daily subcutaneous injection. Two clinically referenced daily regimens appear in the literature and labeling history.

Standard (Current label-based): 1.4 mg once daily
Alternative (Legacy trials): 2 mg once daily
Reconstitution for practical measuring : For this 10 mg vial, both tables use 3 mL (≈3.33 mg/mL). That keeps each injection ≤1.0 mL and comfortably above ~10 units.
After reconstitution (formulation-dependent):
- Multi‑dose BAC system (WR‑like): may be kept at room temperature (20–25 °C) for up to 7 days; do not refrigerate.
- Single‑dose (SV‑like): use immediately after mixing; do not store or refrigerate; discard unused solution.
Unmixed vials : store at controlled room temperature; protect from light (follow product‑specific guidance).

Dosing & Reconstitution Guide

Educational guide for reconstitution and dosing protocol

Standard / Gradual Approach — Label‑Based (3 mL = ≈3.33 mg/mL)

WEEK	DAILY DOSAGE	UNITS (mL) PER INJECTION
Weeks 1–12	1.4 mg (1400 mcg) once daily (7×/week)	42 units (0.42 mL)
Weeks 13–16 (Optional)	1.4 mg once daily (7×/week)	42 units (0.42 mL)

Reconstitute a 10 mg vial with 3.0 mL to yield ≈3.33 mg/mL. Each 1.4 mg dose equals ~0.42 mL (42 units) on a 100‑unit insulin syringe.

Using aseptic technique, draw 3.0 mL diluent (Sterile or Bacteriostatic Water, per lab SOP).
Direct the stream down the vial wall; gently swirl to dissolve (avoid vigorous shaking/foaming).
After mixing:
- If using a multi-dose BAC system (WR-like): keep at room temperature (20–25 °C) and use for up to 7 days; do not refrigerate; discard after day 7.
- If using a single-dose system (SV-like): administer immediately; do not store or refrigerate; discard any unused solution.

Advanced / Aggressive Approach — Legacy Trials (3 mL = ≈3.33 mg/mL)

WEEK RANGE	DAILY DOSAGE (MG)	UNITS (PER INJECTION)
Weeks 1–12	2 mg (2000 mcg) once daily (7×/week)	60 units (0.60 mL)
Weeks 13–16 (Optional)	2 mg once daily (7×/week)	60 units (0.60 mL)

With 3.0 mL reconstitution (≈3.33 mg/mL), each 2 mg dose equals ~0.60 mL (60 units) — well within a standard 1 mL insulin syringe and comfortably above the ~10‑unit minimum guideline.

Reconstitute with 3.0 mL as above for easy measurement.
Gently swirl until clear; avoid foaming.
After mixing:
- WR‑like multi‑dose: room temperature use for up to 7 days; do not refrigerate; discard after day 7.
- SV‑like single‑dose:inject immediately; do not store or refrigerate; discard remainder.

Protocol Overview

Evidence supports once‑daily subcutaneous dosing of tesamorelin for ≥8–12 weeks.

Goal : Reduce visceral adipose tissue and improve metabolic parameters
Schedule : Daily injections (choose either 1.4 mg or 2 mg)
Dose Range : 1.4 mg (current label) or 2 mg (legacy trials)
Reconstitution : Both tables use 3 mL (≈3.33 mg/mL) to keep injections ≤1 mL and ≥10 units
Storage after mixing :WR‑like multi‑dose — up to 7 days at room temp; SV‑like single‑dose — use immediately; in both, do not refrigerate reconstituted solution.

Dosing Protocol

Choose one daily regimen and remain consistent.

Storage Instructions

Follow formulation‑specific instructions; do not refrigerate reconstituted tesamorelin.

Unmixed (lyophilized) vials : Store at controlled room temperature (≈20–25 °C / 68–77 °F), protected from light in original packaging.
After reconstitution :
- WR-like multi-dose (BAC): store at room temperature (20–25 °C) and use for up to 7 days; do not refrigerate; discard remaining solution after day 7.
- SV-like single-dose: use immediately; do not store or refrigerate; discard any unused solution.
Avoid multiple freeze-thaw cycles

Suppilies Needed

Estimate vials based on your chosen regimen and cycle length (daily injections, 7×/week).

Peptide Vials (10 mg each) :
- 1.4 mg daily: 8 wks (56 days) = 78.4 mg ≈ 8 vials;12 wks (84 days) = 117.6 mg ≈ 12 vials; 16 wks (112 days) = 156.8 mg ≈ 16 vials.
- 2 mg daily: 8 wks = 112 mg ≈ 12 vials; 12 wks = 168 mg ≈ 17 vials; 16 wks = 224 mg ≈ 23 vials.
Insulin Syringes :1 per injection (e.g., 56 for 8 weeks; 84 for 12 weeks; 112 for 16 weeks)

Important Notes

Key considerations when working with tesamorelin.

Use new, sterile insulin syringes; rotate injection sites (abdomen; avoid navel, scars, bruised areas).
Common reactions include injection‑site redness/itching, arthralgia, edema, or paresthesias; monitor and seek professional advice for concerning symptoms.
Monitor glucose in those at risk; review contraindications (e.g., active malignancy) against official labeling.
If a calculated dose ever falls <~10 units (not typical here), consider 50‑ or 30‑unit syringes for precision.

How This Works

Tesamorelin is a synthetic analog of growth hormone–releasing hormone (GHRH) that binds pituitary GHRH receptors, increasing pulsatile GH secretion and raising IGF‑1. Clinical studies demonstrated reductions in visceral adipose tissue and favorable effects on certain metabolic markers in indicated populations.

Potential Benefits & Side Effects

Observed in clinical research; individual responses vary.

Potential Benefits : Reduction in visceral adipose tissue; improvements in triglycerides and other lipid measures in some studies; increases in IGF‑1.
Common Side Effects: Injection‑site reactions, arthralgia/myalgia, edema, paresthesias; usually reversible upon dose adjustment or discontinuation.
Precautions : Not for active malignancy; consider pituitary axis conditions and glycemic status; review full safety information in official labeling.

Lifestyle Factors

Support favorable outcomes with fundamentals:

Injection Technique

General subcutaneous administration considerations.

Clean vial stopper and skin with alcohol pads; use a fresh needle and syringe.
Pinch subcutaneous tissue; inject at 45–90° depending on needle length and body fat.
Inject slowly; apply gentle pressure after withdrawing the needle; do not rub.
Dispose of sharps properly; never reuse needles.

Recommended Source

We recommend Go Alpha Labs for high‑purity Tesamorelin (10 mg).

Why Go Alpha Labs?

Important Note:

This guide is for educational and research use only. It does not provide medical advice or directions for patient care. Always follow applicable regulations and consult qualified professionals.

References:

Source	Link
EGRIFTA WR™ Prescribing Information (2025) – multi-dose with BAC; one reconstituted vial provides daily doses for 7 consecutive days; room-temperature storage (no refrigeration)	View Source
EGRIFTA SV® Prescribing Information – daily 1.4 mg; reconstitute and use immediately; do not refrigerate reconstituted solution	View Source
EGRIFTA SV® HCP — Reconstitution – “Once reconstituted, administer immediately”	View Source
EGRIFTA SV® HCP — Storage – non-reconstituted vials stored at room temperature; keep out of light	View Source
Drugs.com — Tesamorelin / EGRIFTA WR – patient storage note: discard unused after 7 days; room-temperature storage	View Source
EMPR (2025) – new WR formulation approved; WR and SV not substitutable; room-temperature storage after reconstitution	View Source
Falutz et al., N Engl J Med (2007) – randomized trial showing VAT reduction with daily tesamorelin (2 mg)	View Source
Stanley et al., JAMA (2014) – effects on visceral and hepatic fat metrics over 6 months	View Source
JCEM (2010) – pooled/extension analyses of efficacy and safety	View Source
Fourman et al., Metab & Inflammation (2017) – VAT reduction associations; open-access review	View Source
FDA Original Label (2010) – immediate use after mixing; do not refrigerate reconstituted solution	View Source
Sigma-Aldrich – general peptide handling & storage guidance for research use	View Source

This site is intended for research purposes only. Peptides are not recommended for human consumption.

Dosage Protocol

Dosage Protocol